Table 1.
Demographic and disease characteristics between the usual care and feasibility participants
| Audit (Before) N = 45a | Feasibility (After) N = 24 | |
|---|---|---|
| Hospital site | ||
| Hospital A | 17 (37.8%) | 8 (33.3%) |
| Hospital B | 28 (62.2%) | 16 (66.7%) |
| Age | ||
| Median (range), years | 62.3 (41.9-85.4) | 62.8 (21.0-78.7) |
| Marital Status, n (%) b | ||
| Married / Civil Partnership | 28 (62.2%) | 17 (70.8%) |
| Co-habiting | 4 (8.9%) | 1 (4.2%) |
| Separated / Divorced | 4 (8.9%) | 2 (8.3%) |
| Widowed | 2 (4.4%) | 1 (4.2%) |
| Single | 2 (4.4%) | 3 (12.5%) |
| Employment, n (%)c | ||
| Full time | 9 (20.0%) | 2 (8.3%) |
| Part time | 2 (4.4%) | 4 (16.7%) |
| Unable to work | 4 (8.9%) | 1 (4.2%) |
| Retired | 23 (51.1%) | 15 (62.5%) |
| Unemployed (not looking) | 3 (6.7%) | 0 |
| Student | 0 | 1 (4.2%) |
| Education, n (%)c | ||
| Basic school | 11 (24.4%) | 6 (25.0%) |
| Beyond minimum school leaving age | 12 (26.7%) | 7 (29.2%) |
| Degree or professional qualification | 18 (40.0%) | 10 (41.7%) |
| Diagnostic stage: | ||
| Stage 1C/2 | 8 (17.8%) | 5 (20.8%) |
| Stage 3A/3B | 5 (11.1%) | 4 (16.6%) |
| Stage 3C | 20 (44.4%) | 14 (58.3%) |
| Stage 4 | 12 (26.7%) | 1 (4.2%) |
| Origin of cancer: | ||
| Ovary | 26 (57.8%) | 16 (66.7%) |
| Peritoneal | 9 (20.0%) | 4 (16.7%) |
| Fallopian | 10 (22.2%) | 4 (16.7%) |
| Histology: | ||
| Serous | 37 (82.2%) | 20 (83.3%) |
| Clear cell | 3 (6.7%) | 2 (8.3%) |
| Endometriod | 2 (3.5%) | 0 |
| Mucinous | 1 (1.8%) | 2 (8.3%) |
| Mixed | 1 (1.8%) | 0 |
| Unknown | 1 (1.8%) | 0 |
| Tumour grade: | ||
| Poorly differentiated | 39 (86.7%) | 19 (79.2%) |
| Other (e.g. moderate, well differentiated) | 4 (8.9%) | 4 (16.7%) |
| Unknown | 2 (4.4%) | 1 (4.2%) |
| BRCA status: | ||
| No abnormality | 32 (71.1%) | 19 (79.2%) |
| BRCA confirmed | 7 (15.6%) | 2 (8.3%) |
| Not tested | 6 (13.3%) | 3 (12.5%) |
| Time since last treatment completed: | ||
| Median (Range), days | 39.0 (4-153) | 412.5 (32-3262) |
| < 12 months | 45 (100%) | 11 (45.8%) |
| > 12 months | 0 | 13 (54.2%) |
| Number (%) who relapsed during the study period: | 24 (53.5%) | 7 (29.2%) |
| Median months to relapse (patient being informed) since last treatment end | 6 | 13 |
| Range (min-max) | 10 (2-12) | 44 (5-49) |
| Baseline QOL outcomes, mean (s.d): | ||
| FACT-O total score, possible range: 0-152 | 118.9 (18.11) | 122.2 (24.77) |
| FACT-G score, possible range: 0-108 | 85.6 (14.61) | 88.3 (19.30) |
| - Physical subscale, possible range: 0-28 | 23.3 (3.79) | 24.8 (3.33) |
| - Social subscale, possible range: 0-28 | 24.3 (4.26) | 23.3 (7.70) |
| - Emotional subscale, possible range: 0-24 | 17.7 (4.58) | 18.2 (5.31) |
| - Functional subscale, possible range: 0-28 | 20.3 (5.57) | 22.0 (6.68) |
| EQ 5D-VAS, possible range 0-100 | 78.7 (13.49 | 84.7 (13.52) |
| QLACS fear of recurrence subscale, possible range 4-28 | 14.2 (6.20) | 13.8 (5.91) |
| Self-efficacy total score, possible range 6-60 | 47.8 (10.81) | 49.2 (11.68) |
| PAM 13 score, possible range 0-100 | 61.7 (13.67) | 64.6 (15.68) |
aThree audit participants did not return the baseline demographic/computer use questionnaire.
bTwo audit participants did not answer the marital status questions.
cOne further audit participant and one feasibility participant did not answer the employment and education questions.
Abbreviations: FACT-O Functional Assessment Cancer Therapy-Ovarian, FACT-G Functional Assessment Cancer Therapy-General, EQ. 5D-VAS, EuroQol 5 Dimension Visual Analog Scale, QLACS Quality of Life in Adult Cancer Survivors, PAM Patient Activation Measure